Prostate Cancer Features Archive

Prostate Cancer Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL

Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL

Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.

General Oncology Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

General Oncology Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

General Oncology The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

Dr Vorobiof discusses the important patient factors that can be missed via standard data collection methods for those with cancer.

Prostate Cancer Prognostic Model for Survival in Metastatic Prostate Cancer

Prognostic Model for Survival in Metastatic Prostate Cancer

Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.

Prostate Cancer Anticarcinogenic Activity of Fish Oil Explored in Study

Anticarcinogenic Activity of Fish Oil Explored in Study

Omega-3 fatty acids found in fish oil act through a host receptor, GPR120, to confer anti-prostate cancer effects. Additional studies are underway.

General Oncology Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

General Oncology Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

General Oncology Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Prostate Cancer Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer

Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer

Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.

General Oncology Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

General Oncology Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Prostate Cancer Genetic Counseling Recommended for Advanced Prostate Cancer

Genetic Counseling Recommended for Advanced Prostate Cancer

A new white paper emphasizes the benefits of germline testing.

General Oncology Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

General Oncology FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

General Oncology Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Prostate Cancer IL-23 Drives Castration-Resistant Prostate Cancer

IL-23 Drives Castration-Resistant Prostate Cancer

A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.

General Oncology Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Prostate Cancer Gene Variant May Affect Response to Abiraterone in Certain Men with Prostate Cancer

Gene Variant May Affect Response to Abiraterone in Certain Men with Prostate Cancer

The breakdown of the medication abiraterone, which can be accelerated by the presence of a specific gene variant, produces drug metabolites that are suspected to play a role in the progression of prostate cancer to castration-resistant forms of disease.

General Oncology Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

General Oncology Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Prostate Cancer New Therapeutic Directions in the Management of Prostate Cancer

New Therapeutic Directions in the Management of Prostate Cancer

According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.

General Oncology ARID1A Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

New findings bolster the case for the predictive utility of ARID1A mutations.

General Oncology Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

General Oncology Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

General Oncology Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Prostate Cancer Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

General Oncology Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Prostate Cancer Could Diet Adjustment Prevent Aggressive Prostate Cancer?

Could Diet Adjustment Prevent Aggressive Prostate Cancer?

A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.

General Oncology The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

General Oncology HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Prostate Cancer Diet and Dosage: How Much Could Patients Save?

Diet and Dosage: How Much Could Patients Save?

Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.

Prostate Cancer Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.

General Oncology Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

General Oncology Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

Phase 1 trials should be considered therapeutic options for some patients.

Side Effect Management Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Prostate Cancer Confronting Racial Disparities in Prostate Cancer Survival Outcomes

Confronting Racial Disparities in Prostate Cancer Survival Outcomes

African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.

General Oncology Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

General Oncology Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

General Oncology Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

General Oncology Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Prostate Cancer Are Liquid Biopsies Trustworthy?

Are Liquid Biopsies Trustworthy?

A study could not determine whether one liquid biopsy panel is more accurate than another overall.

Side Effect Management Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Prostate Cancer Emerging Therapies for Prostate Cancer

Emerging Therapies for Prostate Cancer

New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.

General Oncology Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

General Oncology Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Prostate Cancer Prostate Cancer: Hypofractionated Radiotherapy's Role in Post-operative Settings

Prostate Cancer: Hypofractionated Radiotherapy's Role in Post-operative Settings

Hypofractionated radiotherapy's role in postoperative settings remains unclear and awaits outcomes from ongoing studies.

General Oncology Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

General Oncology Cannabis for Cancer: An Uncertain Future

Cannabis for Cancer: An Uncertain Future

While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.

General Oncology Can Understanding the Gut Microbiome Improve Clinical Oncology?

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.

Prostate Cancer Prostate Cancer and Radiation Colitis

Prostate Cancer and Radiation Colitis

Up to 20% of patients with prostate cancer treated with radiation therapy — external or internal via brachytherapy — will develop radiation colitis.

Prostate Cancer The Potential of Radium-223 in Modern Prostate Cancer Treatment

The Potential of Radium-223 in Modern Prostate Cancer Treatment

More evidence may be needed to understand the safety and efficacy of radium-223 in combination with abiraterone or enzalutamide.

General Oncology Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.

General Oncology Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.

General Oncology The Warburg Effect: Can Cancer Be Starved of Sugar?

The Warburg Effect: Can Cancer Be Starved of Sugar?

A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.

Prostate Cancer Does Education Level Predict PSA Screening and Prostate Cancer Survival?

Does Education Level Predict PSA Screening and Prostate Cancer Survival?

Socioeconomic status, including education and income level, appears to be tied to prostate-specific antigen test results and prostate cancer treatment and survival, but the exact nature of these associations is not yet clear.

General Oncology Genetic Predisposition to Cancer: Where Are We Now?

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.

General Oncology Mobile Apps: The Future of Cancer Care?

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.

General Oncology Spontaneous Regression of Cancer: Explanations and Predictions

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

Prostate Cancer Knowns and Unknowns in the Clinical Application of CTC Testing for Prostate Cancer

Knowns and Unknowns in the Clinical Application of CTC Testing for Prostate Cancer

Cancer Therapy Advisor asked Dr David Graham and Dr Alexander Kutikov about the state of the science of circulating tumor cell testing in prostate cancer, as well as this emerging field's potential clinical applications.

General Oncology Establishing Links Between Germline Mutations and Oncogenesis

Establishing Links Between Germline Mutations and Oncogenesis

In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.

General Oncology Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Prostate Cancer Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.

General Oncology Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

Prostate Cancer Racial Disparities in Prostate Cancer Outcomes: An Elusive Explanation

Racial Disparities in Prostate Cancer Outcomes: An Elusive Explanation

Increased insurance and clinical trial access, plus diversification of the medical workforce, may help to close treatment gaps.

General Oncology Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

General Oncology Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

Prostate Cancer Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.

General Oncology Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Prostate Cancer Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.

General Oncology Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?

Prostate Cancer Prostate Cancer Treatment: Abiraterone and Other Hormonal Therapies Being Studied

Prostate Cancer Treatment: Abiraterone and Other Hormonal Therapies Being Studied

More studies are needed to define the role of intratumoral androgen production and mCRPC resistance to hormonal therapies, and to determine if inhibitors of other steroidogenesis enzymes can be synergistic with abiraterone.

General Oncology Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.

Prostate Cancer Liquid Biopsy for Patients With Prostate Cancer May Determine Drug Treatment Response

Liquid Biopsy for Patients With Prostate Cancer May Determine Drug Treatment Response

A recent study suggests that a liquid biopsy may help oncologists to determine which patients with prostate cancer are likely to respond to enzalutamide or abiraterone.

General Oncology Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

General Oncology Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

Prostate Cancer Prostate Cancer: Treatment Choices and Patient-reported Outcomes

Prostate Cancer: Treatment Choices and Patient-reported Outcomes

Two recent studies provide men diagnosed with localized prostate cancer with important information about the adverse events of treatment choices.

General Oncology Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Prostate Cancer Non-invasive Biomarkers for Metastatic Prostate Cancer

Non-invasive Biomarkers for Metastatic Prostate Cancer

Can liquid biopsy and molecular imaging biomarkers help inform more precise management of patients with metastatic prostate cancer?

General Oncology Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.

General Oncology Incorporating Evolutionary Theory Into Oncology

Incorporating Evolutionary Theory Into Oncology

Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.

General Oncology Treeomics: A Mathematical Tool for Predicting Metastases

Treeomics: A Mathematical Tool for Predicting Metastases

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.

Genitourinary Cancers Symposium 2017 Explaining Androgen Receptor-indifferent Prostate Cancer

Explaining Androgen Receptor-indifferent Prostate Cancer

Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.

Prostate Cancer Prostate Cancer: In Search of Predictive Biomarkers for Immunotherapy

Prostate Cancer: In Search of Predictive Biomarkers for Immunotherapy

Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.

Prostate Cancer PSA Nadir Identifies High-risk Cases of Localized Prostate Cancer

PSA Nadir Identifies High-risk Cases of Localized Prostate Cancer

PSA nadir greater than 0.5 ng/mL may serve as a surrogate marker to identify men with localized prostate cancer at high risk of mortality.

Prostate Cancer Prostate Cancer: Future of Research and Treatment

Prostate Cancer: Future of Research and Treatment

Recent discoveries of germline mutations are driving research in novel treatments, including immunotherapies, for prostate cancer.

Prostate Cancer Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.

Prostate Cancer Metastatic Prostate Cancer to the Gastrointestinal Tract

Metastatic Prostate Cancer to the Gastrointestinal Tract

Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.

General Oncology Vitamin D and Cancer: An Unclear Relationship

Vitamin D and Cancer: An Unclear Relationship

According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.

Prostate Cancer GATA2 in Prostate Cancer: A Promising Biomarker

GATA2 in Prostate Cancer: A Promising Biomarker

The pioneer transcription factor GATA2 has been implicated in prostate tumorigenesis, tumor aggressiveness, treatment resistance, and metastasis, making it a promising biomarker.

General Oncology The Dashboard of Happiness

The Dashboard of Happiness

Dr Barbara Burtness of Yale University's School of Medicine discusses the relationship between happiness and clinical practice in oncology.

General Oncology Survival After Pediatric Cancer: Reducing the Lifetime Burden

Survival After Pediatric Cancer: Reducing the Lifetime Burden

A study of self-reported health status shows the need for physicians to consider the overall well-being of pediatric cancer survivors, for life.

General Oncology Determining the Role of Gender in Oncology Trial and Treatment Outcomes

Determining the Role of Gender in Oncology Trial and Treatment Outcomes

Differences between the sexes are known in a variety of cancers, but the reasons remain unclear.

Supportive Care Seven States Approve Some Form of Marijuana Initiative

Seven States Approve Some Form of Marijuana Initiative

CTA spoke with Judith A. Paice, PhD, RN, to better understand how clinicians are reacting to these legalizations and how she responds to patients asking about cannabis use.

General Oncology Watson: A Glorified Search Engine?

Watson: A Glorified Search Engine?

Watson, hoped to be a major source for clinicians, is limited by an inability to interpret clinical trials.

General Oncology Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?

Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?

Drugmaker funding for patient advocacy groups might be an important but neglected factor in rising drug prices.

Prostate Cancer Developing microRNA Biomarkers for Prostate Cancer

Developing microRNA Biomarkers for Prostate Cancer

Short, noncoding regulatory stretches of RNA known as microRNA hold promise as prostate cancer biomarkers.

Prostate Cancer Looking to the Genome for Prostate Cancer Biomarkers

Looking to the Genome for Prostate Cancer Biomarkers

Researchers are trying to develop prostate cancer biomarkers that can predict treatment effects, to spare patients toxicities associated with unhelpful regimens.

General Oncology Clinical Trial Reporting in the United States: Limitations of Strained Resources

Clinical Trial Reporting in the United States: Limitations of Strained Resources

Guidelines and technology are changing, but as the number of clinical trials increases, ensuring that trials are reported will be an increasingly difficult task.

General Oncology Darwinian Oncology Comes of Age: Evolutionary Biologists Offer Competing Theories of Cancer

Darwinian Oncology Comes of Age: Evolutionary Biologists Offer Competing Theories of Cancer

Proponents of competing evolutionary theories seek to explain—and combat—oncogenesis.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs